PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Exogenous PS (300-800 mg/d) is absorbed efficiently, crosses the blood-brain barrier, and may safely slow, halt, or reverse biochemical alterations associated with brain aging [PMID:25933483]
PS-containing nasal instillation induced Tr1 cells in airway tissues and boosted allergen-specific immunotherapy via the TIM3-PI3K-AKT pathway [PMID:38008186]
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 25933483 (2015) — Phosphatidylserine and the human brain. · Nutrition (Burbank, Los Angeles County, Calif.)
- 2.PMID: 24992464 (2014) — Phosphatidylserine in the brain: metabolism and function. · Progress in lipid research
- 3.PMID: 20192774 (2010) — The distribution and function of phosphatidylserine in cellular membranes. · Annual review of biophysics
- 4.PMID: 23775696 (2013) — Phosphatidylserine-mediated cellular signaling. · Advances in experimental medicine and biology
- 5.PMID: 38008186 (2023) — Phosphatidylserine promotes immunotherapy for airway allergy. · Immunology letters